Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Dechra makes and sells veterinary medicines for pets and farm animals, selling to veterinarians around the world.
Dechra is a veterinary medicine company. It makes the drugs and treatments that vets reach for when a dog's skin flares up, when a cat's hormones go haywire, or when a horse or a cow needs medical care. Its biggest specialty is skin and hormone care for pets, but it also sells a wide range of other products for pets and farm animals. The customer is almost always the veterinarian, not the pet owner directly โ Dechra sells to vets, who then prescribe or dispense the medicine to the animal's owner.
The business rests on a simple but powerful idea: vets are busy and loyal, and once a clinic trusts a brand of, say, ear drops or a thyroid pill, it tends to keep buying it. Dechra builds that trust through a large, steady catalog of products rather than one blockbuster drug, and it sells across many countries. That spread means no single market or single product carries the whole company. The company grew for years by buying smaller veterinary brands and folding them into its own sales network, which is a cheap way to add products that vets already know. Its main products fall into a few buckets: medicines for companion animals like dogs and cats, products for farm animals such as horses and livestock, and a smaller line of specialized diets and care items. Skin and hormone treatments are the heart of the pet side, and that focus matters because pets live longer and owners spend more on them than they used to. Dechra also sells to vets through its own distribution and via partners, which lets it reach clinics in places where it doesn't have a big local team.
The company's biggest vulnerability is that it plays in a regulated, competitive space. Rival animal-health giants such as Zoetis and Merck (which owns a large animal-health business) are far bigger and spend heavily on research and marketing. Dechra's edge is specialty focus and relationships with vets, not scale. It also depends on vets continuing to buy branded products rather than cheaper generics, and on regulators approving its products in each country. In late 2023, the private equity firm EQT agreed to buy Dechra and take it private, which ended its run as a London-listed public company โ a sign that outside investors saw steady cash flows worth owning.
Saved answer ยท last researched 15 Nov 2026